- Home
- IMCR vs AMPH Comparison
IMCR vs AMPH Comparison
Compare IMCR & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- AMPH
- Stock Information
- Founded
- IMCR 2008
- AMPH 1996
- Country
- IMCR United Kingdom
- AMPH United States
- Employees
- IMCR N/A
- AMPH N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- AMPH Health Care
- Exchange
- IMCR Nasdaq
- AMPH Nasdaq
- Market Cap
- IMCR 1.7B
- AMPH 2.5B
- IPO Year
- IMCR 2021
- AMPH 2014
- Fundamental
- Price
- IMCR $32.93
- AMPH $51.45
- Analyst Decision
- IMCR Buy
- AMPH Buy
- Analyst Count
- IMCR 14
- AMPH 4
- Target Price
- IMCR $74.75
- AMPH $63.00
- AVG Volume (30 Days)
- IMCR 267.8K
- AMPH 268.7K
- Earning Date
- IMCR 11-05-2024
- AMPH 11-06-2024
- Dividend Yield
- IMCR N/A
- AMPH N/A
- EPS Growth
- IMCR N/A
- AMPH 62.07
- EPS
- IMCR N/A
- AMPH 3.15
- Revenue
- IMCR $280,914,000.00
- AMPH $712,891,000.00
- Revenue This Year
- IMCR $25.60
- AMPH $18.04
- Revenue Next Year
- IMCR $10.63
- AMPH $4.41
- P/E Ratio
- IMCR N/A
- AMPH $16.26
- Revenue Growth
- IMCR 27.95
- AMPH 31.80
- 52 Week Low
- IMCR $29.72
- AMPH $36.56
- 52 Week High
- IMCR $76.98
- AMPH $65.92
- Technical
- Relative Strength Index (RSI)
- IMCR 52.76
- AMPH 59.40
- Support Level
- IMCR $31.10
- AMPH $49.38
- Resistance Level
- IMCR $35.47
- AMPH $51.84
- Average True Range (ATR)
- IMCR 1.49
- AMPH 1.25
- MACD
- IMCR 0.17
- AMPH 0.10
- Stochastic Oscillator
- IMCR 51.98
- AMPH 78.90
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.